Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation
NCT ID: NCT00143117
Last Updated: 2012-11-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
460 participants
INTERVENTIONAL
2004-08-31
2005-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
UK-390,957
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Tucson, Arizona, United States
Pfizer Investigational Site
Anaheim, California, United States
Pfizer Investigational Site
Atherton, California, United States
Pfizer Investigational Site
Beverly Hills, California, United States
Pfizer Investigational Site
Laguna Woods, California, United States
Pfizer Investigational Site
Newport Beach, California, United States
Pfizer Investigational Site
Redwood City, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
Tarzana, California, United States
Pfizer Investigational Site
Walnut Creek, California, United States
Pfizer Investigational Site
Aurora, Colorado, United States
Pfizer Investigational Site
Waterbury, Connecticut, United States
Pfizer Investigational Site
Aventura, Florida, United States
Pfizer Investigational Site
New Port Richey, Florida, United States
Pfizer Investigational Site
Pembroke Pines, Florida, United States
Pfizer Investigational Site
Evansville, Indiana, United States
Pfizer Investigational Site
Fort Wayne, Indiana, United States
Pfizer Investigational Site
Indianapolis, Indiana, United States
Pfizer Investigational Site
Michigan City, Indiana, United States
Pfizer Investigational Site
Lexington, Kentucky, United States
Pfizer Investigational Site
Madisonville, Kentucky, United States
Pfizer Investigational Site
Metairie, Louisiana, United States
Pfizer Investigational Site
Milford, Massachusetts, United States
Pfizer Investigational Site
Saint Clair Shores, Michigan, United States
Pfizer Investigational Site
Minneapolis, Minnesota, United States
Pfizer Investigational Site
Southhaven, Mississippi, United States
Pfizer Investigational Site
Kansas City, Missouri, United States
Pfizer Investigational Site
Reno, Nevada, United States
Pfizer Investigational Site
Edison, New Jersey, United States
Pfizer Investigational Site
New Brunswick, New Jersey, United States
Pfizer Investigational Site
Voorhees Township, New Jersey, United States
Pfizer Investigational Site
Albany, New York, United States
Pfizer Investigational Site
Endwell, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
West Seneca, New York, United States
Pfizer Investigational Site
Williamsville, New York, United States
Pfizer Investigational Site
Charlotte, North Carolina, United States
Pfizer Investigational Site
Durham, North Carolina, United States
Pfizer Investigational Site
Beachwood, Ohio, United States
Pfizer Investigational Site
Tulsa, Oklahoma, United States
Pfizer Investigational Site
Germantown, Tennessee, United States
Pfizer Investigational Site
Knoxville, Tennessee, United States
Pfizer Investigational Site
Memphis, Tennessee, United States
Pfizer Investigational Site
Milan, Tennessee, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Fort Worth, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Plano, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Tacoma, Washington, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A3871022
Identifier Type: -
Identifier Source: org_study_id